Targeting HER2 + breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles

Journal of Controlled Release

Volumn 172, Issue 2, 2013, Pages 395-404

  Owen, Shawn C ^a,b   Patel, Nish ^a,c   Logie, Jennifer ^a,b   Pan, Guohua ^a,c   Persson, Helena ^a,c   Moffat, Jason ^a,c   Sidhu, Sachdev S ^a,c   Shoichet, Molly S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antibody; Antibody drug conjugate; Herceptin; Nanoparticle

Indexed keywords

ANTIBODY BINDING SITES; ANTIBODY-DRUG CONJUGATES; CELL SURFACE RECEPTORS; CELLULAR LOCALIZATION; HERCEPTIN; HUMANIZED MONOCLONAL ANTIBODY; INTRACELLULAR TRAFFICKING; POLYMERIC NANOPARTICLES;

ANTIBODIES; CELL MEMBRANES; EPITOPES; MOLECULES; MONOCLONAL ANTIBODIES; NANOPARTICLES;

POLYMERS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NANOPARTICLE; TRASTUZUMAB;

ANTIBODY COMBINING SITE; ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; DNA SEQUENCE; DRUG CONJUGATION; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; LYSOSOME; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; ZETA POTENTIAL;

ANTIBODY; ANTIBODY-DRUG CONJUGATE; HERCEPTIN; NANOPARTICLE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES, ANTIBODY; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOCONJUGATES; LYSOSOMES; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDE LIBRARY; RECEPTOR, ERBB-2;

EID: 84887068994     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.07.011     Document Type: Article

References (53)

1. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 5 2005 341 354 (Pubitemid 40637826)
2. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565 (Pubitemid 32197693)
3. K. Roepstorff, L. Grovdal, M. Grandal, M. Lerdrup, and B. van Deurs Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer Histochem. Cell Biol. 129 2008 563 578
4. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N. Engl. J. Med. 357 2007 39 51 (Pubitemid 47026733)
5. J. Albanell, J. Codony, A. Rovira, B. Mellado, and P. Gascon Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 A. LlombartBosch, V. Felipo, New Trends in Cancer for the 21st Century 2003 253 268 (Pubitemid 37176793)
6. J. Baselga, and J. Albanell Mechanism of action of anti-HER2 monoclonal antibodies Ann. Oncol. 12 2001 35 41
7. C.D. Austin, A.M. De Maziere, P.I. Pisacane, S.M. van Dijk, C. Eigenbrot, M.X. Sliwkowski, J. Klumperman, and R.H. Scheller Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Mol. Biol. Cell 15 2004 5268 5282 (Pubitemid 39564723)
8. T. Vu, and F.X. Claret Trastuzumab: updated mechanisms of action and resistance in breast cancer Front. Oncol. 2 2012 62 68
9. M.V. Karamouzis, P.A. Konstantinopoulos, and A.G. Papavassiliou Trastuzumab - mechanism of action and use N. Engl. J. Med. 357 2007 39 51
10. M.X. Sliwkowski, J.A. Lofgren, G.D. Lewis, T.E. Hotaling, B.M. Fendly, and J.A. Fox Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin. Oncol. 26 1999 60 70 (Pubitemid 29411434)
11. A. Sorkin, and L.K. Goh Endocytosis and intracellular trafficking of ErbBs Exp. Cell Res. 315 2009 683 696
12. Y. Kitano, S. Umemura, H. Ohbayashi, M. Takenaga, and R.Y. Osamura Assessment of a new anti-HER2 monoclonal antibody, SV2-61 gamma: a best concordance with HER2 FISH Appl. Immunohistochem. Mol. Morphol. 15 2007 389 393 (Pubitemid 350307843)
13. J.L. Nordstrom, S. Gorlatov, W. Zhang, Y. Yang, L. Huang, S. Burke, H. Li, V. Ciccarone, T. Zhang, J. Stavenhagen, S. Koenig, S.J. Stewart, P.A. Moore, S. Johnson, and E. Bonvini Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc gamma receptor binding properties Breast Cancer Res. 13 2011
14. A.S. Tabatabaei-Panah, A.H. Zarnani, S. Montaser-Kouhsari, M. Chamankhah, R. Ghods, A.A. Bayat, G.E. Kazemi-Sefat, S.A.R. Mahmoudi, M.O. Karampour, S. Shojaeian, and M. Jeddi-Tehrani Production and characterizing anti-HER2 monoclonal antibodies Yakhteh 10 2008 109 120
15. A.L.A. Wong, and S.-C. Lee Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer Int. J. Breast Cancer 2012 2012 (415170-415170)
16. J. Bostrom, L. Haber, P. Koenig, R.F. Kelley, and G. Fuh High affinity antigen recognition of the dual specific variants of Herceptin is entropy-driven in spite of structural plasticity PLoS One 6 2011 e17887
17. S.S. Sidhu, and S. Koide Phage display for engineering and analyzing protein interaction interfaces Curr. Opin. Struct. Biol. 17 2007 481 487 (Pubitemid 47451773)
18. F.A. Fellouse, K. Esaki, S. Birtalan, D. Raptis, V.J. Cancasci, A. Koide, P. Jhurani, M. Vasser, C. Wiesmann, A.A. Kossiakoff, S. Koide, and S.S. Sidhu High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries J. Mol. Biol. 373 2007 924 940 (Pubitemid 47498435)
19. H.K. Erickson, P.U. Park, W.C. Widdison, Y.V. Kovtun, L.M. Garrett, K. Hoffman, R.J. Lutz, V.S. Goldmacher, and W.A. Blattler Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 66 2006 4426 4433
20. S. Girish, M. Gupta, B. Wang, D. Lu, I.E. Krop, C.L. Vogel, H.A. Burris, P.M. LoRusso, J.H. Yi, O. Saad, B. Tong, Y.W. Chu, S. Holden, and A. Joshi Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer Cancer Chemother. Pharmacol. 69 2012 1229 1240
21. G.D. Lewis Phillips, G. Li, D.L. Dugger, L.M. Crocker, K.L. Parsons, E. Mai, W.A. Blättler, J.M. Lambert, R.V.J. Chari, R.J. Lutz, W.L.T. Wong, F.S. Jacobson, H. Koeppen, R.H. Schwall, S.R. Kenkare-Mitra, S.D. Spencer, and M.X. Sliwkowski Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68 2008 9280 9290
22. M. Shi, K. Ho, A. Keating, and M.S. Shoichet Doxorubicin-conjugated immuno-nanoparticles for intracellular anticancer drug delivery Adv. Funct. Mater. 19 2009 1689 1696
23. V.P. Torchilin Targeted polymeric micelles for delivery of poorly soluble drugs Cell. Mol. Life Sci. 61 2004 2549 2559 (Pubitemid 39591627)
24. E. Wagner Programmed drug delivery: nanosystems for tumor targeting Expert. Opin. Biol. Ther. 7 2007 587 593 (Pubitemid 46707182)
25. Y. Cheng, L. Zhao, Y. Li, and T. Xu Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives Chem. Soc. Rev. 40 2011 2673 2703
26. Y. Namiki, T. Fuchigami, N. Tada, R. Kawamura, S. Matsunuma, Y. Kitamoto, and M. Nakagawa Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring Acc. Chem. Res. 44 2011 1080 1093
27. L. Nobs, F. Buchegger, R. Gurny, and E. Allemann Current methods for attaching targeting ligands to liposomes and nanoparticles J. Pharm. Sci. 93 2004 1980 1992 (Pubitemid 39045480)
28. C.J. Sunderland, M. Steiert, J.E. Talmadge, A.M. Derfus, and S.E. Barry Targeted nanoparticles for detecting and treating cancer Drug Dev. Res. 67 2006 70 93 (Pubitemid 43765051)
29. E.L. Sievers, and P.D. Senter Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64 2013 15 29
30. F. Fay, and C.J. Scott Antibody-targeted nanoparticles for cancer therapy Immunotherapy 3 2011 381 394
31. D. Schrama, R.A. Reisfeld, and J.C. Becker Antibody targeted drugs as cancer therapeutics Nat. Rev. Drug Discov. 5 2006 147 159
32. T. Junttila, G. Li, K. Parsons, G. Phillips, and M. Sliwkowski Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Breast Cancer Res. Treat. 128 2011 347 356
33. M.S.K. Sutherland, R.J. Sanderson, K.A. Gordon, J. Andreyka, C.G. Cerveny, C.P. Yu, T.S. Lewis, D.L. Meyer, R.F. Zabinski, S.O. Doronina, P.D. Senter, C.L. Law, and A.F. Wahl Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates J. Biol. Chem. 281 2006 10540 10547 (Pubitemid 43864594)
34. P.D. Senter, and E.L. Sievers The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nature Biotech 30 2012 631 637
35. S. Bhattacharyya, R.D. Singh, R. Pagano, J.D. Robertson, R. Bhattacharya, and P. Mukherjee Switching the targeting pathways of a therapeutic antibody by nanodesign Angew. Chem. Int. Ed. 51 2012 1563 1567
36. S. Bhattacharyya, R. Bhattacharya, S. Curley, M.A. McNiven, and P. Mukherjee Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis Proc. Natl. Acad. Sci. U. S. A. 107 2010 14541 14546
37. J. Liu, P. Kopeckova, P. Buehler, P. Wolf, H. Pan, H. Bauer, U. Elsaesser-Beile, and J. Kopecek Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells Mol. Pharm. 6 2009 959 970
38. M. Shi, J.H. Wosnick, K. Ho, A. Keating, and M.S. Shoichet Immuno-polymeric nanoparticles by Diels-Alder chemistry Angew. Chem. Int. Ed. Engl. 46 2007 6126 6131 (Pubitemid 47290969)
39. J. Lu, and M.S. Shoichet Self-assembled polymeric nanoparticles of organocatalytic copolymerizated d, l-lactide and 2-methyl 2-carboxytrimethylene carbonate Macromolecules 43 2010 4943 4953
40. G.C. Howard, and M.R. Kaser Making and Using Antibodies: A Practical Handbook 2006 Taylor & Francis
41. J. Lu, S.C. Owen, and M.S. Shoichet Stability of self-assembled polymeric micelles in serum Macromolecules 44 2011 6002 6008
42. D.P.Y. Chan, S.C. Owen, and M.S. Shoichet Double click: dual functionalized polymeric micelles with antibodies and peptides Bioconjug. Chem. 24 2013 105 113
43. G.C. Howard, and M.R. Kaser Making and Using Antibodies: A Practical Handbook 2007 CRC/Taylor & Francis Boca Raton, FL
44. K.W. Dunn, M.M. Kamocka, and J.H. McDonald A practical guide to evaluating colocalization in biological microscopy Am. J. Physiol. Cell Physiol. 300 2011 C723 C742
45. J. Kao, K. Salari, M. Bocanegra, Y.L. Choi, L. Girard, J. Gandhi, K.A. Kwei, T. Hernandez-Boussard, P. Wang, A.F. Gazdar, J.D. Minna, and J.R. Pollack Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery PLoS One 4 2009
46. J.R. Casey, S. Grinstein, and J. Orlowski Sensors and regulators of intracellular pH Nat. Rev. Mol. Cell Biol. 11 2010 50 61
47. L. Neckers Hsp90 inhibitors as novel cancer chemotherapeutic agents Trends Mol. Med. 8 2002 S55 S61
48. W.C. Widdison, S.D. Wilhelm, E.E. Cavanagh, K.R. Whiteman, B.A. Leece, Y. Kovtun, V.S. Goldmacher, H.S. Xie, R.M. Steeves, R.J. Lutz, R. Zhao, L.T. Wang, W.A. Blattler, and R.V.J. Chari Semisynthetic maytansine analogues for the targeted treatment of cancer J. Med. Chem. 49 2006 4392 4408 (Pubitemid 44036683)
49. G. Valabrega, F. Montemurro, and M. Aglietta Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann. Oncol. 18 2007 977 984 (Pubitemid 47050487)
50. P. Nagy, E. Friedlander, M. Tanner, A.I. Kapanen, K.L. Carraway, J. Isola, and T.M. Jovin Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res. 65 2005 473 482
51. K. Lin, and J. Tibbitts Pharmacokinetic considerations for antibody drug conjugates Pharm. Res. 29 2012 2354 2366
52. J.Y. Axup, K.M. Bajjuri, M. Ritland, B.M. Hutchins, C.H. Kim, S.A. Kazane, R. Halder, J.S. Forsyth, A.F. Santidrian, K. Stafin, Y. Lu, T. Hon, A.J. Seller, S.L. Biroce, A. Szydlik, J.K. Pinkstaff, F. Tian, S.C. Sinha, B. Felding-Habermann, V.V. Smider, and P.G. Schultz Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U. S. A. 109 2012 16101 16106
53. A.M. Wu, and P.D. Senter Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 23 2005 1137 1146 (Pubitemid 41486395)